



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

Application Number	10/777,820
Filing Date	February 12, 2004
First Named Inventor	Collins <i>et al.</i>
Group Art Unit	Unassigned 1654
Examiner	Unassigned
Attorney Docket Number	11138.105024 MAYO 1001 CON

3466095 1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
[Handwritten marks]	AA	3,627,788	A	Bouchaudon	11-27-1968	
	AB	3,936,440	A	Nath	02-03-1976	
	AC	3,981,863	A	Niswender <i>et al.</i>	09-21-1976	
	AD	4,209,614	A	Bernstein <i>et al.</i>	06-24-1980	
	AE	4,279,859	A	Gutcho <i>et al.</i>	07-21-1981	
	AF	4,283,342	A	Yollees	08-11-1981	
	AG	4,301,140	A	Frank <i>et al.</i>	11-17-1981	
	AH	4,465,775	A	Houts	08-14-1984	
	AI	4,612,302	A	Szabo <i>et al.</i>	09-16-1986	
	AJ	4,684,620	A	Hruby <i>et al.</i>	08-04-1987	
	AK	4,853,371	A	Coy <i>et al.</i>	08-01-1989	
	AL	5,308,606	A	Wilson <i>et al.</i>	05-03-1994	
	AM	5,405,598	A	Schinazi <i>et al.</i>	08-11-1995	
	AN	5,405,839	A	Toraya <i>et al.</i>	04-11-1995	
	AO	5,428,023	A	Russell-Jones <i>et al.</i>	06-27-1995	
	AP	5,449,720	A	Russell-Jones <i>et al.</i>	09-12-1995	
	AQ	5,462,724	A	Schinazi <i>et al.</i>	10-31-1995	
	AR	5,514,695	A	Bergeron	05-07-1996	
	AS	5,548,064	A	Russell-Jones <i>et al.</i>	08-20-1996	
	AT	5,574,018	A	Habberfield <i>et al.</i>	11-12-1996	
	AU	5,589,463	A	Russell-Jones <i>et al.</i>	12-31-1996	
	AV	5,599,796	A	Schinazi <i>et al.</i>	02-04-1997	
	AW	5,608,060	A	Axworthy <i>et al.</i>	03-04-1997	
	AX	5,739,313	A	Collins <i>et al.</i>	04-14-1998	
	AY	5,807,832	A	Russell-Jones <i>et al.</i>	09-15-1998	
	AZ	5,840,880	A	Morgan, Jr. <i>et al.</i>	11-24-1998	
	AAA	5,869,465	A	Morgan, Jr. <i>et al.</i>	02-09-1999	
	AAB	5,869,466	A	Russell-Jones <i>et al.</i>	02-09-1999	
	AAC	5,872,107	A	Schinazi <i>et al.</i>	02-16-1999	
	AAD	5,877,165	A	Miura <i>et al.</i>	03-02-1999	
	AAE	5,936,082	A	Bauer	08-10-1999	

Examiner Signature

David Ruckman

Date Considered

5-3-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/777,820
				Filing Date	February 12, 2004
				First Named Inventor	Collins <i>et al.</i>
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	7	Attorney Docket Number	11138.105024 MAYO 1001 CON

3466095 1.DOC

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
<i>DL</i>	BA	6,004,533	A	Collins <i>et al.</i>	12-21-1999	
	BB	6,074,625	A	Hawthorne <i>et al.</i>	06-13-1900	
	BC	6,083,926	A	Morgan <i>et al.</i>	07-04-2000	
	BD	6,083,966	A	Bergeron, Jr.	07-04-2000	
	BE	6,096,290	A	Collins <i>et al.</i>	08-01-2000	
	BF	6,150,341	A	Russell-Jones, <i>et al.</i>	11-21-2000	
	BG	6,180,766	B1	Schinazi <i>et al.</i>	01-30-2001	
	BH	6,211,355	B1	Collins <i>et al.</i>	04-03-2001	
	BI	6,262,253	B1	Russell-Jones, <i>et al.</i>	07-17-2001	
	BJ	6,315,978	B1	Grissom <i>et al.</i>	11-13-01	
	BK	2002/0042394	A1	Hogenkamp <i>et al.</i>	04-11-2002	
	BL	2002/0049155	A1	Hogenkamp	04-25-2002	
	BM	2002/0151525	A1	Collins <i>et al.</i>	10-17-2002	
	BN	2003/0018009	A1	Collins	01-23-2003	
	BO	2003/0144198	A1	Collins	07-31-2003	
	BP	6,613,305	A1	Collins <i>et al.</i>	09-02-2003	

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ²	Number	Kind Code ³ (if known)			
<i>X</i>	BQ	AU	04490099	A1	Biotech Australia Pty. Ltd.	01-05-2000	
<i>X</i>	BR	DE	1,811,518		Rhone-Poulenc S.A. (Bouchardon) <i>Chem. Abstr. 71:91866s (1969)</i>	07-10-1969	
<i>X</i>	BS	EP	0 005 834	A1	E.R. Squibb & Sons, Inc.	12-12-1979	
<i>X</i>	BT	EP	0 069 450	A1	Technicon Instruments Corp.	01-12-1983	
<i>X</i>	BU	EP	0 165 716	A1	Micromedic Systems Inc.	12-27-1985	
<i>X</i>	BV	JP	58-046027	A2	Nippon Meiji Fijitsukusu KK	03-17-1983	
<i>X</i>	BW	WO	89/01475	A1	Celltech Ltd.; Parker; Millican	02-23-1989	
<i>X</i>	BX	WO	92/09610	A1	University of California	06-11-1992	
<i>X</i>	BY	WO	92/13571	A1	Dow Chemical Company	08-20-1992	
<i>X</i>	BZ	WO	94/27613	A1	Biotech Australia Pty. Ltd. <i>et al.</i>	12-08-1994	
<i>X</i>	BAA	WO	94/27641	A1	Biotech Australia Pty. Ltd. <i>et al.</i>	12-08-1994	
<i>X</i>	BAB	WO	95/27723	A1	Morgan; Wilbur; Pathare	10-19-1995	

Examiner Signature	<i>David Lyden</i>	Date Considered	5-3-06
-----------------------	--------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/777,820
				Filing Date	February 12, 2004
				First Named Inventor	Collins <i>et al.</i>
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	7	Attorney Docket Number	11138.105024 MAYO 1001 CON

3466095 I.DOC

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ²	Number	Kind Code ³ (if known)			
DL	CA	WO	96/04016	A1	Amgen Inc.	02-15-1996	
DL	CB	WO	96/27641	A1	BioTech Australia	12-08-1994	
X	CC	WO	96/31243	A1	The DuPont Merck Pharm. Co.	10-10-1996	
X	CD	WO	97/14711	A1	Receptagen; Univ. Washington	04-24-1997	
X	CE	WO	97/18231	A1	Regents of Univ. Minnesota	05-22-1997	
X	CF	WO	97/33627	A2	The DuPont Merck Pharm. Co.	09-18-1997	
X	CG	WO	98/08859	A1	Univ. Utah Res. Found.	03-05-1998	
X	CH	WO	99/65930	A1	Biotech Australia Pty. Ltd.	12-23-1999	
X	CI	WO	00/45857	A2	Schering AG	08-10-2000	
X	CJ	WO	00/62808	A2	Univ. Minnesota	10-26-2000	
X	CK	WO	00/74721	A1	Biotech Australia Pty. Ltd.	12-14-2000	
DL	CL	WO	01/28592	A1	Mayo Found.; U. Minnesota	04-26-2001	
DL	CM	WO	01/28595	A1	Mayo Found.; U. Minnesota	04-26-2001	
DL	CN	WO	01/30967	A2	Univ. Utah Res. Found. <i>et al.</i>	05-03-2001	
DL	CO	WO	01/92283	A2	Mayo Found.; U. Minnesota	12-06-2001	
DL	CP	WO	01/92288	A2	Collins; Mayo Found.; U. Minn.	12-06-2001	
DL	CQ	WO	02/042318	A2	Collins; Mayo Found.; U. Minn.	05-30-2002	
DL	CR	WO	02/055530	A2	Mayo Found.; U. Minnesota	07-18-2002	
DL	CS	WO	03/000010	A2	Collins	01-21-2003	
DL	CT	WO	03/025139	A2	Mayo Found.	03-27-2003	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T 6
DL	CU	ALAM, G. <i>et al.</i> , "Boronated compounds for neutron capture therapy," <i>Strahlentherapie und Onkologie</i> , 165(2/3):121-123 (1989).					
DL	CV	ALLEN, R.H., <i>et al.</i> , "Isolation of gastric vitamin B ₁₂ -binding proteins using affinity chromatography," <i>J. Biol. Chem.</i> , 248(10):3660-3669 (May 25, 1973).					
DL	CW	ALLEN, R.H., <i>et al.</i> , "Isolation of vitamin B ₁₂ -binding proteins using affinity chromatography," <i>J. Biol. Chem.</i> , 247(23):7695-7701 (December 10, 1972).					
X	CX	AMAGASAKI, T., <i>et al.</i> , "Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells," <i>Blood</i> , 76(7):1380-1386, (October 1, 1990).					

Examiner Signature	<i>David R. Chan</i>	Date Considered	5-3-06
-----------------------	----------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		
				Application Number	10/777,820	
				Filing Date	February 12, 2004	
				First Named Inventor	Collins <i>et al.</i>	
				Group Art Unit	Unassigned	
				Examiner Name	Unassigned	
Sheet	4	of	7	Attorney Docket Number		11138.105024 MAYO 1001 CON

3466095 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>DL</i>	DA	ANTON, D.L., <i>et al.</i> , "Carbon-13 nuclear magnetic resonance studies of the monocarboxylic acids of cyanocobalamin. Assignments of the B-, D-, and E-monocarboxylic acids," <i>J. Am. Chem. Soc.</i> , 102(7):2215-2219 (March 26, 1980).	
X	DB	ANTON, D.L., <i>et al.</i> , "The synthesis and properties of four spin-labeled analogs of adenosylcobalamin," <i>J. Biol. Chem.</i> 255(10):4507-4510 (May 25, 1980).	
X	DC	BEGLEY, J.A., <i>et al.</i> , "Cobalamin metabolism in cultured human chorionic villus cells," <i>J. Cell Physiol.</i> 156(1):43-47 (July 1993).	
X	DD	BERNHÄNER, K., <i>et al.</i> , "Zur Chemie und Biochemie der Corrinoides," <i>Biochem. Z.</i> 344:289-309 (1966).	
X	DE	BLOMQUIST, L., <i>et al.</i> , "Uptake of labelled vitamin B ₁₂ and 4-iodophenylalanine in some tumors of mice," <i>Experientia</i> , 25(3):294-296 (March 15, 1969).	
X	DF	BREEMAN, W.A., <i>et al.</i> , "Indium-111 labeled DTPA- and DOTA-bombesin analogs for receptor scintigraphy and radiotherapy," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):102P, Abstract no. 413 (May 1999 supplement).	
<i>DL</i>	DG	BROAN, C. J., <i>et al.</i> , "Synthesis and complexation behaviour of an effective octadentate complexone 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis[methylene(methylphosphinic acid)]," <i>J. Chem. Soc. Chem. Comm.</i> , 23:1739-1741 (1990).	
X	DH	COLLINS, D.A., <i>et al.</i> , "Transcobalamin II receptor imaging via radiolabeled diethylene-triaminepentaacetate cobalamin analogs," <i>J. Nucl. Med.</i> , 38(5):717-723 (May 1997).	
X	DI	COLLINS, D.A., <i>et al.</i> , "Tumor imaging via indium 111-labeled DTPA-adenosylcobalamin," <i>Mayo Clin. Proc.</i> , 74(7):687-691 (July 1999).	
X	DJ	COOPER, B.A., <i>et al.</i> , "Selective uptake of specifically bound cobalt-58 vitamin B ₁₂ by human and mouse tumour cells," <i>Nature</i> , 191, 393-395 (July 1961).	
X	DK	De JONG, M., <i>et al.</i> , "Radionuclide therapy using radiolabeled somatostatin analogs in tumor-bearing rats," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):102, Abstract no. 414 (May 1999 supplement).	
<i>DL</i>	DL	ELLENBOGEN, L., "Absorption and transport of cobalamin: Intrinsic factor and the transcobalamins," <i>Cobalamin: Biochemistry and Pathophysiology</i> , Babior, Ed., Wiley, New York (1975), Chapter 5.	
<i>DL</i>	DM	FAIRCHILD, R.G., <i>et al.</i> , "Current status of 10-B-neutron capture therapy: enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical evaluation," <i>Int. J. Radiation Oncology, Biology, Physics</i> , 11(4):831-840 (April 1985).	

Examiner Signature	<i>David L. Lukan</i>	Date Considered	5-3-06
--------------------	-----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0631-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/777,820
				Filing Date	February 12, 2004
				First Named Inventor	Collins <i>et al.</i>
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	5	of	7	Attorney Docket Number	11138.105024 MAYO 1001 CON

3466095 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
X	EA	FINKLER, A.E., <i>et al.</i> , "Nature of the relationship between vitamin B12 binding and cell uptake," <i>Arch. Biochem. Biophys.</i> , 120(1):79-85 (April 1967).	
X	EB	FLODIN, H., <i>et al.</i> , "Accumulation of labelled vitamin B12 in some transplanted tumours," <i>Int. J. Cancer</i> , 3(5):694-699 (September 15, 1968).	
DE	EC	GABEL, D., "Tumor-Seeking Compounds for Boron Neutron Capture Therapy: Synthesis and Biodistribution," <i>Clinical Aspects of Neutron Capture Therapy</i> , Ralph G. Fairchild <i>et al.</i> , eds.; Plenum Press, New York, (undated), 233-241.	
DE	ED	GABEL, D., <i>et al.</i> , "Monte Carlo simulation of the biological effect of the ¹⁰ B(n,α) ⁷ Li reaction in cells and tissue and its implication for boron neutron capture therapy," <i>Radiation Research</i> , 111:14-25 (1987).	
X	EE	HALL, C.A., <i>et al.</i> , "Cyclic activity of the receptors of cobalamin bound to transcobalamin-H," <i>J. Cell. Physiol.</i> , 133(1):187-191 (October 1987).	
DE	EF	HATANAKA, H., "A revised boron-neutron capture therapy for malignant brain tumors," <i>Journal of Neurology</i> , 209:81-94 (1975).	
X	EG	HATANAKA, H., <i>et al.</i> , "Chapter XXV: Clinical Experience of Boron-Neutron Capture Therapy for Gliomas -- A Comparison with Conventional Chemo-Immuno-Radiotherapy," pp. 349-379. (undated)	
DE	EH	HAWTHORNE, M.F., <i>et al.</i> , "Preparation of tumor-specific boron compounds. 1. <i>In vitro</i> studies using boron-labeled antibodies and elemental boron as neutron target(s)," <i>Journal of Medicinal Chemistry</i> , 15(5):449-452 (1992).	
DE	EI	HOGENKAMP, H. <i>et al.</i> , "Synthesis and Characterization of nido-Carborane-Cobalamin Conjugates," <i>Nucl. Med. & Biol.</i> , 27:89-92 (2000).	
X	EJ	HOGENKAMP, H.P.C., Chemical synthesis and properties of analogs of adenosylcobalamin, <i>Biochemistry</i> , 13(13):2736-2740 (1974).	
DE	EK	HOGENKAMP, H.P.C., <i>et al.</i> , "Carbon-13 nuclear magnetic resonance studies of adenosylcobalamin and alkylcorrinoids, selectively enriched with carbon-13," <i>Biochemistry</i> , 14(16):3707-3714 (1975).	
DE	EL	ICHIHASHI, M., <i>et al.</i> , "Specific killing effect of ¹⁰ B ₁ -para-boronophenylalanine in thermal neutron capture therapy of malignant melanoma: <i>In vitro</i> radiobiological evaluation," <i>The Journal of Investigative Dermatology</i> , 78(3):215-218 (1982).	
DE	EM	JACOBSEN, D.W., <i>et al.</i> , "Rapid purification of cobalamin-binding proteins using immobilized aminopropylcobalamin," <i>Anal. Biochem.</i> , 113:164-171 (1981).	
DE	EN	KIKUGAWA, K., <i>et al.</i> , "Direct halogenation of sugar moiety of nucleosides," <i>Tetrahedron Letters</i> , 1971(2):87-90 (1971).	
X	EO	KAHL, S.B., <i>et al.</i> , "Chemical and biological studies on boronated tetraphenyl porphyrins," <i>Boron Chemistry</i> , 61-67	

Examiner Signature	<i>David R. Hagan</i>	Date Considered	5-3-06
--------------------	-----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/777,820
				Filing Date	February 12, 2004
				First Named Inventor	Collins <i>et al.</i>
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	6	of	7	Attorney Docket Number	11138.105024 MAYO 1001 CON

3466095 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	FA	LASTER, B.H., <i>et al.</i> , "Biological efficacy of a boronated porphyrin as measured in cell culture," <i>Strahlentherapie und Onkologie</i> , 165(2/3):203-205 (1989).	
X	FB	LINDEMANS, J., <i>et al.</i> , "Uptake of transcobalamin II-bound cobalamin by HL-60 cells: effects of differentiation induction," <i>Experimental Cell Research</i> , 184(2):449-460 (Oct. 1989).	
X	FC	LUO, S.Z., "Studies on bone tumor therapeutic radiopharmaceuticals. IV. Investigation of the structure-activity relationships (SARS) of ¹⁵³ Sm-aminocarboxylate complexes," in Poster Sessions, Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):316P, Abstract no. 1386 (May 1999 supplement).	
	FD	McBRIDE, W.J., "A general method for the introduction of metal binding ligands onto the side chains of peptides during peptide synthesis," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):124P, Abstract no. 500 (May 1999 supplement).	
	FE	MEASE, R.C., <i>et al.</i> , "Indium-111 CDTA-(aminostyryl)pyridiniumum (di-X-asp) dyes: synthesis, canine and human leukocyte labeling, and serum stability," in Poster Sessions, Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):318P, Abstract no. 1396 (May 1999 supplement).	
	FF	MISHIMA, Y., <i>et al.</i> , "Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking B-compound," <i>Lancet</i> , 2(8659):388-389 (August 12, 1989).	
X	FG	MISHIMA, Y., <i>et al.</i> , "First human clinical trial of melanoma neutron capture. Diagnosis and therapy," <i>Strahlentherapie und Onkologie</i> , 165(2/3):251-254 (1989).	
X	FH	MOMEN, A., <i>et al.</i> , "Impact of high resolution bone spect imaging of the thoracolumbar spine on patient management in oncology," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):124P, Abstract no. 500 (May 1999 supplement).	
	FI	NAKAGAWA, T., <i>et al.</i> , "Syntheses of chlorpromazine undecahydrododecaborate and nonahydrodecaborate – promising agents for neutron capture therapy of malignant melanoma," <i>Chem. Pharm. Bull. (Tokyo)</i> , 24(4):778-781 (1976) [UDC 547.869.2.04; 547.244.04]	
	FJ	NEXO, E., "Cobalamin-binding proteins," Chapter 30 in <i>Vitamin B₁₂ and B₁₂ Proteins</i> , B. Krantler <i>et al.</i> , Eds., Wiley & Sons, New York (1997), pp. 461-475.	
	FK	NORENBERG, J.P., "[²¹³ Bi-DOTA ⁰ , Tyr ¹]octreotide (²¹³ Bi-DOTATOC) in peptide receptor radionuclide therapy (PRRT)," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):103, Abstract no. 415 (May 1999 supplement).	

Examiner Signature		Date Considered	5-3-06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/777,820
				Filing Date	February 12, 2004
				First Named Inventor	Collins <i>et al.</i>
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	7	of	7	Attorney Docket Number	11138.105024 MAYO 1001 CON

3466095 1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	GA	ORDER, S.E., <i>et al.</i> , "Use of isotopic immunoglobulin in therapy," <i>Cancer Res.</i> , 40:3001-3007 (August 1980)	
	GB	PISAL, S.S., <i>et al.</i> , "Formulation of nasal gels of Vitamin B12-1: Effect of additives on thermodynamic properties of pluronic PF-127 gels," <i>Indian J. Pharm. Sci.</i> (May-June 2002), accessed November 12, 2002, at www.indianpharma.org/may-june2002/fnasalgels.html .	
	GC	PRIMUS, F.J., <i>et al.</i> , "Bispecific antibody mediated targeting of nido-carboranes to human colon carcinoma cells," <i>Bioconjugate Chemistry</i> , 7:532-535 (1996).	
	GD	RAO, P.S., <i>et al.</i> , "TC-99M labeled peptide for imaging infection," in Poster Sessions, Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):319P, Abstract no. 1398 (May 1999 supplement).	
	GE	RAPPAZZO, M.E., <i>et al.</i> , "Transport function of transcobalamin H," <i>J. Clin. Invest.</i> , 51(7), 1915-1918 (July 1972).	
	GF	ROE, D.G., <i>et al.</i> , "Combinatorially designed technetium radiopharmaceuticals (CDTR TM)," in Scientific Papers, Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):123P, Abstract No. 499 (May 1999 supplement).	
	GG	RUSER, G., <i>et al.</i> , "Synthesis and evaluation of two new bidentate carboxymethylated tetrazamacrocyclic chelating agents for protein labeling with Indium-111," <i>Bioconj. Chem.</i> , 1:345-349 (1990).	
	GH	SATTELBERGER, A.R., <i>et al.</i> , "Nuclear medicine finds the right chemistry," <i>Nature Biotechnology</i> , 849-850, Vol. 17, September 1999.	
	GI	SMELTZER, C.C., <i>et al.</i> , "Synthesis and characterization of fluorescent cobalamin (CobalaFluor) derivatives for imaging," <i>Organic Letters</i> , 3(6):799-801 (2001).	
	GJ	TORAYA, T., <i>et al.</i> , "Preparation, properties and biological activities of succinyl derivatives of vitamin B ₁₂ ," <i>Bioinorg. Chem.</i> , 4:245-255 (1975).	
	GK	WILBUR, D.S., <i>et al.</i> , "Evaluation of Biotin-Dye Conjugates for Use in an HPLC Assay to Assess Relative Binding of Biotin Derivatives with Avidin and Streptavidin," <i>Bioconjugate Chem.</i> , 11(4), 584-598 (July-August 2000).	
	GL	WILBUR, D.S., <i>et al.</i> , "Biotin Reagents for Antibody Pretargeting. 4. Selection of Biotin Conjugates for in Vivo Application Based on Their Dissociation Rate from Avidin and Streptavidin," <i>Bioconjugate Chem.</i> , 11(4), 569-583 (July-August 2000).	
	GM	WU, C., VIRZI, F., and HNATOWICH, D.J., "Investigations of N-linked macrocycles for ¹¹¹ In and ⁹⁰ Y labeling of proteins," <i>Nucl. Med. Biol.</i> , 19(2):239-244 (1992) [<i>Int. J. Radiat. Appl. Instrum. Part B</i>].	

Examiner Signature		Date Considered	5-3-06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.